美国 · 平台与数据 · MarketBeat
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch

详细摘要
Axsome Therapeutics (NASDAQ:AXSM) executives said growth in new prescriptions for AUVELITY and an expanded sales team are positioning the company for further growth following the drug’s launch for Alzheimer’s disease agitation. Speaking at the UBS Biopharma Conference in London, Chief Financial Off
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.marketbeat.com)




